Latest stories on ZVRA
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
GlobeNewswire50 · neutralgeneral
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
Business Insider50 · neutralgeneral
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal
Seeking Alpha64 · neutralanalyst
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor
Seeking Alpha67 · bullishproduct/pr
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Zevra Therapeutics to Present at Upcoming Investor Conferences
Business Insider56 · neutralgeneral
Zevra Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Business Insider63 · neutralproduct/pr
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim
The Fly42 · neutralanalyst
Zevra Therapeutics Q2 Earnings Call Highlights
Yahoo Top63 · neutralearnings
Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041
Seeking Alpha63 · neutralproduct/pr
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Zevra Therapeutics, Inc. GAAP EPS of $0.14 beats by $0.03, revenue of $39.7M beats by $5.82M
Seeking Alpha68 · bullishearnings
ZEVRA THERAPEUTICS, INC. (ZVRA) files 8-K
SEC 8-K50 · neutralgeneral
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
StockTitan50 · neutralearnings
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Business Insider56 · neutralgeneral
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
PR Newswire34 · bearishgeneral
ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics
PR Newswire34 · bearishgeneral
BTIG cuts Zevra Therapeutics price target on EU setback
Investing.com Analyst Ratings34 · bearishanalyst
Guggenheim cuts Zevra stock price target to $24 on EU setback
Investing.com Analyst Ratings34 · bearishanalyst